David Esposito

David has built and scaled multiple healthcare companies that resulted in the successful growth of his companies which leading to exits to strategic buyers. As a member of Inspirotec's Scientific and Strategic Advisory Board, David's extensive experiences and successful U.S. launch of new innovative products in the allergen & allergy testing and laboratory services will help drive Inspirotec's AirAnswers® patented air allergen devise, testing business, and consult services into its next growth phase. Recent past successes include CEO: Armune BioScience (sold to Exact Sciences [EXAS] Dec.2017) and US President: Phadia US/AB which launched and grew Immunocap™ blood allergen testing companyImmunoCAP® Specific IgE Blood Test (sold to Thermo Fisher Scientific [TMO] for $3.5 billion Sept. 2011).